NASDAQ:KPRX Kiora Pharmaceuticals Q4 2024 Earnings Results & Report $2.46 -0.01 (-0.40%) As of 12:45 PM Eastern This is a fair market value price provided by Massive. Learn more. Kiora Pharmaceuticals missed analyst earnings expectations and met on revenue in its Q4 2024 results, released March 25, 2025. The company reported EPS of -$1.04 versus the -$0.64 consensus estimate, while revenue of $0.75 million matched the $0.75 million estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMarch 25, 2025TimeBefore Market OpensConference Call7:00 AM ET Kiora Pharmaceuticals EPS ResultsActual EPS-$1.04Consensus EPS -$0.64Beat/MissMissed by -$0.40One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersKiora Pharmaceuticals Revenue ResultsActual Revenue$0.75 millionExpected Revenue$0.75 millionBeat/MissMet ExpectationsYoY Revenue GrowthN/AUpcoming EarningsKiora Pharmaceuticals' Q3 2026 earnings is estimated for Friday, November 6, 2026, based on past reporting schedules, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesPress Release (8-K)Annual Report (10-K)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Kiora Pharmaceuticals Q4 2024 Earnings FAQ Did Kiora Pharmaceuticals beat earnings estimates for Q4 2024? Kiora Pharmaceuticals (NASDAQ:KPRX) reported earnings of -$1.04 per share for Q4 2024, missing the consensus estimate of -$0.64. The report was announced on Tuesday, March 25, 2025. What was Kiora Pharmaceuticals' revenue for Q4 2024? Kiora Pharmaceuticals reported revenue of $0.75 million for Q4 2024, against a consensus estimate of $0.75 million. When is Kiora Pharmaceuticals' next earnings date? Kiora Pharmaceuticals' next earnings date is estimated for Friday, November 6, 2026. MarketBeat tracks confirmed and estimated earnings dates for Kiora Pharmaceuticals on the company's earnings history page. Kiora Pharmaceuticals Earnings HeadlinesContrasting Jaguar Animal Health (NASDAQ:JAGX) & Kiora Pharmaceuticals (NASDAQ:KPRX)October 7, 2026 | americanbankingnews.comKiora Pharmaceuticals (NASDAQ:KPRX) Shares Down 1.2% - Time to Sell?October 6, 2026 | americanbankingnews.comI have publicly predicted six major American crashes, before each one happened.Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.October 14 at 1:00 AM | Weiss Ratings (Ad)Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory AffairsSeptember 8, 2026 | finance.yahoo.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Joint (JYNT) and Kiora Pharmaceuticals (KPRX)August 9, 2026 | theglobeandmail.comKiora Pharmaceuticals Shareholders Approve Expanded Equity Incentive PlanJune 11, 2026 | tipranks.comSee More Kiora Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kiora Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kiora Pharmaceuticals and other key companies, straight to your email. Email Address About Kiora PharmaceuticalsKiora Pharmaceuticals (NASDAQ:KPRX) is a clinical-stage biotechnology company focused on developing treatments for diseases of the eye. Its research programs address conditions affecting the retina and other ocular tissues, with an emphasis on therapies that may offer new treatment options for patients with limited or no approved alternatives. The company’s pipeline has included KIO-301, an investigational small-molecule photoswitch designed to provide light sensitivity and potentially restore visual function in people with inherited retinal diseases such as retinitis pigmentosa. Kiora has also developed investigational ophthalmic therapies for inflammatory and surface-related eye disorders, including KIO-104 for noninfectious uveitis and KIO-101 for dry eye disease. These candidates remain subject to clinical and regulatory evaluation. Kiora was formerly known as EyeGate Pharmaceuticals and adopted the Kiora Pharmaceuticals name as it expanded its focus on retinal and other ophthalmic diseases. The company is headquartered in the United States and has conducted clinical development activities in the United States and internationally, including Australia. Kiora Pharmaceuticals trades on the Nasdaq under the symbol KPRX.View Kiora Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenPBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough Road Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
